long intergenic non-protein coding RNA 1871Genealiases: []
Q-omics provides the consensus-scored LINC01871 profile across patient tissues and cancer cell-line models. LINC01871 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, LINC01871 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, LINC01871 RNA expression shows 14,397 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight SKCM, COAD, and TGCT as cancer lineages where LINC01871 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01871 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01871 survival associations across molecular data types. LINC01871 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01871 RNA expression–survival associations across cancer types. High LINC01871 expression shows unfavorable associations in LGG, but favorable associations in SKCM, UCEC, HNSC, BLCA and BRCA. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for LINC01871 RNA expression.
This table summarizes LINC01871 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01871. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01871 shows lower tumor expression in COAD, LUSC, BRCA and LUAD and higher tumor expression in KIRC and KIRP. The COAD box plot shows higher LINC01871 RNA expression in normal versus tumor tissue (log2 FC = −1.285, t-test p < 0.001).
This table shows molecular features associated with LINC01871 in patient tissues and cancer cell lines. In patient samples, LINC01871 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
